Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
MIA PaCa-2
gemcitabine
pancreatic cancer
pitavastatin
synergistic anticancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
01
2020
accepted:
13
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2. The anticancer effects of gemcitabine with pitavastatin were evaluated using human MIA PaCa-2 cell line in vitro and in vivo Balb/c murine xenograft tumor model. Cell viability was assessed with CCK-8, and cell migration was stained by crystal violet. Cell cycle distribution, apoptosis and mitochondrial membrane potential were examined by flow cytometry. Activation of drug transporters (hENTs, hCNTs), intracellular drug activating (dCK) and inhibition of inactivating enzymes (RRMs) pathways were assessed by Western blotting analysis. Molecular mechanisms and signaling pathways of apoptosis, necrosis and autophagy also were assessed by Western blotting. We observed that gemcitabine and pitavastatin synergistically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest. Activation of apoptosis/necrosis was confirmed by annexin V/propidium iodide double staining, which showed increasing levels of active caspase 3, cleaved poly(ADP-ribose) polymerase and the RIP1-RIP3-MLKL complex. Moreover, gemcitabine-pitavastatin-mediated S phase arrest downregulated cyclin A2/CDK2 and upregulated p21/p27 in MIA PaCa-2 cells. Furthermore, this combination improved drug cellular metabolism pathway, mitochondria function and activated autophagy as part of the cell death mechanism. In vivo, gemcitabine-pitavastatin effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts without observed adverse effect. Combined gemcitabine-pitavastatin may be an effective novel treatment option for pancreatic cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2.
METHODS
METHODS
The anticancer effects of gemcitabine with pitavastatin were evaluated using human MIA PaCa-2 cell line in vitro and in vivo Balb/c murine xenograft tumor model. Cell viability was assessed with CCK-8, and cell migration was stained by crystal violet. Cell cycle distribution, apoptosis and mitochondrial membrane potential were examined by flow cytometry. Activation of drug transporters (hENTs, hCNTs), intracellular drug activating (dCK) and inhibition of inactivating enzymes (RRMs) pathways were assessed by Western blotting analysis. Molecular mechanisms and signaling pathways of apoptosis, necrosis and autophagy also were assessed by Western blotting.
RESULTS
RESULTS
We observed that gemcitabine and pitavastatin synergistically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest. Activation of apoptosis/necrosis was confirmed by annexin V/propidium iodide double staining, which showed increasing levels of active caspase 3, cleaved poly(ADP-ribose) polymerase and the RIP1-RIP3-MLKL complex. Moreover, gemcitabine-pitavastatin-mediated S phase arrest downregulated cyclin A2/CDK2 and upregulated p21/p27 in MIA PaCa-2 cells. Furthermore, this combination improved drug cellular metabolism pathway, mitochondria function and activated autophagy as part of the cell death mechanism. In vivo, gemcitabine-pitavastatin effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts without observed adverse effect.
CONCLUSION
CONCLUSIONS
Combined gemcitabine-pitavastatin may be an effective novel treatment option for pancreatic cancer.
Identifiants
pubmed: 32606957
doi: 10.2147/CMAR.S247876
pii: 247876
pmc: PMC7306478
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4645-4665Informations de copyright
© 2020 Chen et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur J Pharmacol. 2014 Oct 15;741:8-16
pubmed: 25084222
Int J Cancer. 1977 Jan;19(1):128-35
pubmed: 832918
Strahlenther Onkol. 2015 Jan;191(1):7-16
pubmed: 25252602
Cell Biol Int. 1999;23(1):51-60
pubmed: 10527548
World J Surg Oncol. 2016 Feb 29;14:59
pubmed: 26927942
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Br J Cancer. 2014 Oct 14;111(8):1562-71
pubmed: 25093497
Biochim Biophys Acta. 2011 Jun;1807(6):534-42
pubmed: 20849810
Cell. 1997 Nov 28;91(5):627-37
pubmed: 9393856
Acta Histochem. 2014 Oct;116(8):1454-61
pubmed: 25450902
Cancer Res. 1991 Nov 15;51(22):6110-7
pubmed: 1718594
Mol Med Rep. 2015 Oct;12(4):5012-8
pubmed: 26151733
Drug Des Devel Ther. 2017 Nov 16;11:3273-3280
pubmed: 29180851
Free Radic Biol Med. 2010 Feb 15;48(4):506-12
pubmed: 19969066
J Neurosurg. 2009 Mar;110(3):594-604
pubmed: 19046042
Lipids Health Dis. 2017 Dec 20;16(1):250
pubmed: 29262834
Clin Cancer Res. 2008 Mar 1;14(5):1284-5
pubmed: 18316544
J Clin Oncol. 2000 Jan;18(1):122-30
pubmed: 10623702
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Cancer Res. 2000 Dec 15;60(24):7133-41
pubmed: 11156422
J Biol Chem. 2000 Mar 10;275(10):7087-94
pubmed: 10702275
Cancers (Basel). 2017 Nov 16;9(11):
pubmed: 29144412
Atherosclerosis. 2006 Aug;187(2):301-8
pubmed: 16289073
Int J Oncol. 2003 Oct;23(4):1055-69
pubmed: 12963986
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773-81
pubmed: 16361565
Oncol Rep. 2015 Mar;33(3):1019-39
pubmed: 25607255
Acta Oncol. 2016;55(3):265-77
pubmed: 26213211
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Br J Cancer. 2005 Aug 8;93(3):319-30
pubmed: 16052215
Digestion. 2016;94(4):222-229
pubmed: 28030863
Toxicol Pathol. 1991;19(3):197-205
pubmed: 1780636
Oncol Lett. 2017 Dec;14(6):7993-7999
pubmed: 29344241
Onco Targets Ther. 2016 Aug 29;9:5383-8
pubmed: 27621652
Sci Rep. 2017 Aug 14;7(1):8090
pubmed: 28808351
Drug Metab Dispos. 2011 Mar;39(3):441-7
pubmed: 21106720
Sci Rep. 2017 Jul 14;7(1):5410
pubmed: 28710496
Biomed Pharmacother. 2014 Feb;68(1):65-9
pubmed: 24268811
Pancreas. 1995 Nov;11(4):345-9
pubmed: 8532650
Medicine (Baltimore). 2017 Jul;96(30):e7611
pubmed: 28746215
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
JAMA. 2008 Mar 5;299(9):1019-26
pubmed: 18319412
PLoS One. 2011;6(9):e25207
pubmed: 21966455
Fundam Appl Toxicol. 1994 Jul;23(1):9-20
pubmed: 7958569
J Gastrointest Surg. 2004 Dec;8(8):1072-8
pubmed: 15585396